Allurion’s operating partner in Türkiye.
We are the Master Distributor for the Allurion Swallowable Gastric Balloon and Allurion Virtual Care Suite (VCS) lines across Türkiye and the CIS, and the registration holder and importer in Türkiye — running regulatory affairs, operations and growth under one team. Getting a device onto the shelf is the easy part; selling it off the shelf is the work.
A manufacturer entering this market has two options: buy a report, or work with an operator. We’re the operator. You sign one agreement; the licence, the stock, the field team and the receivables all sit on our side of it.
Allurion Balloon and VCS — Master Distributor, Türkiye and the CIS
Allurion Technologies Inc. — Master Distributor for the Swallowable Gastric Balloon and VCS lines across Türkiye and the CIS. Import, stocking, distribution to authorised centres and the downstream commercial work all run under this authority. Alzey was founded in 2024; field continuity on the product line dates back to 2021. The dated regulatory record lives on the Allurion Türkiye page.
How the B2B2C model works.
A standard distribution agreement has two sides: you sell, the distributor buys. The operation we run has three, and all three have to win on the same transaction. You sell your device, the clinic finds its patient, the patient gets access to treatment.
On the B2B side we build, train and manage the clinic network. On the B2C side we run the patient-facing surfaces, the ad accounts and the intake line with our own team. What joins the two layers is a single CRM and a single field rhythm, because demand is only worth anything once it lands at a centre that can actually take that patient.
B2B · product and trade flow
- Manufacturer
- Alzey
- Authorised centre
- Patient
B2C · demand flow
- Alzey
- Patient demand
- Authorised centre
Medical distribution in Türkiye normally stops at the B2B side: the hospital, the dealer, the physician. Building patient demand is left to the manufacturer or to the clinic. A distribution partner that also runs the demand layer is unusual in this market, and that is where we separate.
The route a device takes.
A market-entry report tells you what the pathway looks like. We hold the pathway: ten steps, from the registration file to the collected receivable, all on our side of the agreement.
The registration file
Everything starts with the file, and the file sits with us. We prepare it, submit it and answer for it.
TİTCK and ÜTS
The licence is taken in Alzey’s name. The product is licensed with TİTCK and entered into ÜTS, Türkiye’s device-tracking registry; both records sit with us.
Import and customs
We import the product ourselves. Customs and freight run through licensed service providers, while the paperwork, the coordination and the responsibility stay with us.
Buffer stock
Buffer stock sits in our own warehouse, so an authorised centre never runs dry.
The authorised centre
The product moves only to authorised centres, and authorisation is a step in this chain rather than a formality.
Physician training
Physicians at authorised centres go through Allurion Academy certification; congress work and KOL relationships run on the same line.
The demand channel
Demand doesn’t arrive on its own. We build it through channels we own: the patient-facing site, the ad accounts, the WhatsApp line, the CRM.
The sale
Our field team runs the sell-through; orders, delivery and after-sales sit with one team.
Receivables and collections
We carry the credit. Channel credit risk sits with us, not with you: you deal with one counterparty, and collections in the field are our problem.
Vigilance
The work doesn’t end at the sale. Vigilance and adverse-event reporting continue under our responsibility as authorised distributor.
One agreement, one accountable counterparty — from licence to collections. No hand-offs between a consultant, an importer and an agency.
What sits inside a registration file.
Most sites cover regulatory affairs with two acronyms. A TİTCK file is eight consecutive pieces of work, each with its own paperwork, owner and calendar. We run all eight in house.
Regulatory feasibility and classification assessment
We establish which class the device falls into in Türkiye and which pathway it has to follow, before a file is opened.
Labelling and Turkish IFU compliance check
Labels, packaging and the instructions for use are prepared in Turkish, with the content the regulation requires.
Technical file compilation and gap analysis
We compile the manufacturer’s technical documentation and list what is missing on one page, ahead of submission.
TİTCK submission and official follow-up
The application is filed in Alzey’s name; correspondence with the authority and the deadlines are ours to manage.
ÜTS registration and product numbering
The product is entered into ÜTS, with singular numbering and notifications running off that record.
Promotional and advertising material compliance review
Everything that reaches the field is reviewed against Turkish advertising rules and the manufacturer’s own brand controls.
Change notifications (minor/major) and renewals
When the product or the file changes we notify it, and the licence renewal is filed on time.
Vigilance and adverse-event reporting
A signal from the field is recorded, reported to the authority and coordinated with the manufacturer.
None of this is a new service line. It is the work every file already goes through, named. Regulatory depth means keeping all eight items on one desk, so none of them travels back to yours.
Three columns, one operation.
Regulatory affairs, operations and growth: on the ground, the three columns work as seven lines. Each comes with its proof.
- Registration and market access
- TİTCK licensing and ÜTS registration run in Alzey’s name in Türkiye. In Kazakhstan (NCEDMD/EAEU), Georgia (RAMA) and Azerbaijan our distribution network is active.
- Import, logistics and stock
- From EXW onwards the chain is ours: import, warehousing and delivery to the centre, with buffer stock underwriting the line.
- Commercial execution
- Sales run through our own field team and a CRM that holds our registered clinics. Receivables management and collections stay with us.
- Demand generation
- The demand channel is ours: patient-facing site, ad accounts, WhatsApp line and CRM. The infrastructure is built; the organic engine is not yet fully running.
- Physician training and KOL
- Training runs through Allurion Academy, with certification; congress presence and KOL relationships sit on the same line.
- Quality and compliance
- Vigilance, adverse-event reporting, marketing compliance (Red/Amber/Green) and data protection live inside the daily operation. The detail is on the Quality & Compliance page.
- Caucasus and Central Asia expansion
- We take the same model into neighbouring markets through a sub-distributor network. In Kazakhstan that network is established and running.
What the network is made of.
“A hundred centres” tells a manufacturer very little on its own. Your question is whether those centres can sell your device. So we describe the network by composition first and by count second.
- Clinics
- Hospitals
- Obesity centres
- Medical-travel agencies
- Physician practices
The 100+ centres we work with are a mix of those five channels. The spine of the network is clinics and bariatric physicians working in obesity and metabolic care; physicians at authorised centres hold Allurion Academy certification. A field team of 5+ people carries this network, and the visit rhythm, the training plan and the receivables follow-up sit with that same team.
Medical-travel agencies are a distinct channel inside that network, and they matter more to an international manufacturer than the label suggests. Türkiye draws a strong inbound patient flow for aesthetic and surgical procedures, and that flow makes demand for premium devices partly independent of the local patient economy. When a centre treats both local and inbound patients, demand for a device line no longer rests on a single patient source.
The commercial stack is ours, and we wrote it.
Underneath the field operation runs software we built ourselves. The clinic network sits in our own CRM; a patient’s first contact lands on the WhatsApp intake line; receivables, collections and conversion are reported out of the same system.
Contact layer
- WhatsApp lead line
- Patient-facing surfaces
- Ad accounts
Operating layer
- Our own clinic CRM
- Network segmentation
- Field visit rhythm
- Quotation generation
Analytics layer
- Receivables and collections analytics
- Conversion optimisation tooling
- Process automation and reporting
What this buys you in practice: we run the commercial infrastructure without depending on an agency or on bought-in software, and when a process has to change, our own team changes it. The schematic above is deliberately abstract: system screens, clinic names and commercial data stay inside.
We build the clinic’s ability to sell.
Regulatory affairs and operations have ten steps. Growth has its own. Training the physician is not enough on its own: the front desk has to answer the phone properly, the clinic has to see its own numbers, and the rhythm has to hold week after week.
- 01
Clinic segmentation and field rhythm
We segment the network by patient profile and capacity, then set a visit and follow-up rhythm for each segment.
- 02
Physician training and Allurion Academy certification
Training runs to certification; congress work and KOL relationships sit on the same line.
- 03
Front-desk conversion programme
The clinic’s first contact is the front desk. We put a frame around how calls are answered, how objections are handled and how conversion is measured: a measurement frame, an objection library, a weekly rhythm and a monthly review with the physician.
- 04
Demand channel and patient routing
Patient flow from our own channels is routed to the authorised centre that can actually take that patient.
- 05
ROI modelled on the clinic’s own numbers
Return is modelled on the clinic’s own patient volume, capacity and cost base. The sheet on the table is the clinic’s sheet.
This methodology has been run in the field: the marketing, patient flow coordination and sales training programmes we have delivered at centres offering 360-degree obesity care now number more than a hundred.
You won’t find a conversion rate, a patient count or a sales figure on this page. What we can share is the methodology and where it has been applied; the numbers belong to the clinic and stay there.
Which lines we can take.
We can’t take every device. The physician profile of our network and our field rhythm work in specific categories; outside them we are probably the wrong partner, and we will say so in the first call. These are the lines we are open to today:
- Obesity and metabolic devices
- Our core line. The physician profile of the network and the field rhythm were built around this category.
- Bariatric and endoscopic devices and consumables
- Lines that reach the same physician and the same procedure setting; our field team keeps the same counterpart.
- Body contouring and aesthetic technologies
- The second device line for centres that carry the patient on after obesity treatment.
- Metabolic monitoring and digital health hardware
- Hardware that sits inside follow-up programmes; the digital side already runs on our own systems.
- Premium device lines aimed at medical travel
- Lines for centres that receive patients from abroad. We run that channel separately.
- Innovative medical solutions
- Devices in categories Türkiye has not defined yet, where clinical adoption and patient demand have to be built together. Building the category is part of the operation.
The lines we represent today, and our capacity in adjacent categories, are recorded on the portfolio page.
What we distribute.
The Allurion Program consists of the Smart Capsule, the Smart Scale, a mobile app and six months of nutritional follow-up. The device holds FDA PMA Class III full approval (23.02.2026); on the CE side, CE 0123 (TÜV SÜD) — Article 120 transition regime.
This page carries no clinical-efficacy or weight figures; the programme definition is structural. The dated summary of regulatory status sits in the band below.
Regulatory status
- FDA
- PMA Class III full approval· 23.02.2026
- CE
- CE 0123 (TÜV SÜD) — Article 120 transition regime
- Türkiye
- TİTCK precautionary decisions lifted as of 19.02.2025
- Registration
- TİTCK / ÜTS registration
Regulatory status may change; consult official TİTCK and FDA records for the current position.
Let’s talk about bringing your device into this market.
This page is written for device manufacturers and their business-development teams. Physicians and clinics looking for programme information will find it on allurion.alzeypartners.co. It shares no clinical-efficacy or weight figures; it is a corporate statement, not marketing.